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PREFACE
Give thanks to the creatures of the world for they bring beauty, joy and
peace.
We mourn the loss of certain species and pray for the deliverance of
endangered ones. Grant them shelter, food, water and fair weather.
Matthew 10:29
For only a few cents you can buy two sparrows, yet not one sparrow falls
to the ground without your Father’s consent.
The study of things caused precedes the study of the cause of things.
Richmond Loh
Murdoch University
Western Australia
2006iv
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ABSTRACT
The pathology of a disfiguring and debilitating fatal disease affecting a
high proportion of the wild population of Tasmanian Devils (Sarcophilus
harrisii) that was discovered is described. The disease, named devil
facial tumour disease (DFTD), has been identified in devils found across
60% of the Tasmanian landscape. The prevalence of this disease was
extremely variable, possibly reflecting seasonal trapping success.
Between 2001 and 2004, 91 DFTD cases were obtained for pathological
description. Grossly, the tumours presented as large, solid, soft tissue
masses usually with flattened, centrally ulcerated and exudative surfaces.
They were typically multi-centric, appearing first in the oral, face or neck
regions. Histologically, the tumours were composed of circumscribed to
infiltrative nodular aggregates of round to spindle-shaped cells often
within a pseudocapsule and divided into lobules by delicate fibrous
septae. They were locally aggressive and metastasised in 65% of cases.
There was minimal cytological differentiation amongst the tumour cell
population under light and electron microscopy. The diagnostic values of
a number of immunohistochemical stains were employed to further
characterise up to 50 representative cases. They were negative for
cytokeratin, epithelial membrane antigen, von Willebrand factor, desmin,
glial fibrillary acid protein, CD16, CD57, CD3 and LSP1. DFTD cells were
positive for vimentin, S-100, melan A, neuron specific enolase,
chromogranin A and synaptophysin.  In conclusion, the morphological
and immunohistochemical characteristics together with the primary
distribution of the neoplasms indicate that DFTD is an undifferentiated
neoplasm of neuroendocrine histogenesis.viii
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